Donepezil Hydrochloride
Product Images NDC 63629-1118

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 63629-1118). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Spl Image1 Structure)

Chemical structure diagram of donepezil hydrochloride showing its molecular framework including methoxy groups, piperidine ring, and benzyl group, along with the hydrochloride component.*

FDA Label Image

Figure 9 (Spl Image10 Figure9)

A line graph depicting the mean change from baseline in ADCS-ADL scores over 6 months of treatment. The graph compares donepezil hydrochloride 10 mg/day to placebo, showing clinical improvement and decline over time with error bars indicating standard error.*

FDA Label Image

Figure 10 (Spl Image11 Figure10)

A line graph comparing the cumulative percentage of patients experiencing changes in ADCS-ADL scores from baseline for Donepezil Hydrochloride 10 mg/day versus placebo. The x-axis shows ADCS-ADL change from baseline, and the y-axis shows cumulative percentage of patients. Donepezil is represented by a filled circle line, placebo by an open square line.*

FDA Label Image

Figure 11 (Spl Image12 Figure11)

A line graph depicting the SIB (Severe Impairment Battery) change from baseline over 24 weeks of drug treatment with donepezil hydrochloride at dosages of 10 mg/day and 23 mg/day. The graph shows clinical improvement and decline on the vertical axis, with points plotted for multiple weeks indicating treatment effect and standard error bars.*

FDA Label Image

Figure 12 (Spl Image13 Figure12)

A line graph showing the cumulative percentage of patients on donepezil hydrochloride at 10 mg/day and 23 mg/day plotted against SIB (Severe Impairment Battery) change from baseline. The x-axis represents the SIB change from baseline, while the y-axis shows the cumulative percentage of patients. Two lines compare the outcomes of the two dosage groups.*

FDA Label Image

Figure 13 (Spl Image14 Figure13)

A bar chart comparing the CIBIC-plus clinical ratings of patients treated with donepezil hydrochloride at 23 mg/day and 10 mg/day. The x-axis shows categories ranging from "Markedly Improved" to "Markedly Worse," and the y-axis shows the percentage of patients in each category. The chart illustrates how patients' clinical status changed during treatment with each dosage.*

FDA Label Image

Principal Display Panel – 23 mg Bottle Label (Spl Image15 Label)

Donepezil Hydrochloride Tablets USP 23 mg label showing the dosage strength prominently. The label includes storage instructions, a barcode, and manufacturer Bryant Ranch Prepack information. The package size is 90 tablets and is marked Rx only.*

FDA Label Image

Figure 1 (Spl Image2 Figure1)

A line graph depicting ADAS-cog change from baseline over 24 weeks of drug treatment, comparing donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo. The y-axis shows mean change from baseline with error bars, indicating clinical improvement or decline, while the x-axis represents weeks of drug treatment, followed by a placebo period.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

Line graph depicting the cumulative percentage of patients versus change from baseline in ADAS-cog scores, comparing treatment groups with donepezil hydrochloride at 10 mg/day, 5 mg/day, and placebo. The graph shows the distribution of cognitive changes with labeled points for 7, 4 points, and no change.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

A bar chart showing the percentage of patients categorized by clinical response to donepezil hydrochloride at doses of 5 mg/day and 10 mg/day, compared to placebo. Categories include Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

A line graph showing ADAS-cog change from baseline mean differences over weeks of drug treatment up to 12 weeks plus a placebo group at week 15. Three groups are compared: donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo. The y-axis measures cognitive change, with clinical improvement above baseline and clinical decline below. Error bars represent standard error (±SE).*

FDA Label Image

Figure 5 (Spl Image6 Figure5)

A cumulative percentage graph showing changes from baseline in ADAS-cog scores for three groups: placebo, donepezil hydrochloride 5 mg/day, and donepezil hydrochloride 10 mg/day. The x-axis represents change from baseline and the y-axis represents cumulative percentage of patients. The graph includes labeled points marking 7 and 4 points improvement and no change, illustrating greater cognitive improvement in the donepezil groups relative to placebo.*

FDA Label Image

Figure 6 (Spl Image7 Figure6)

A bar chart showing the percentage of patients categorized by clinical response to donepezil hydrochloride at daily doses of 5 mg and 10 mg compared to placebo. The response categories on the x-axis range from markedly improved to markedly worse, with the y-axis representing percentage of patients.*

FDA Label Image

Figure 7 (Spl Image8 Figure7)

A line graph showing SIB (Severe Impairment Battery) change from baseline over 6 months of drug treatment comparing donepezil hydrochloride 10 mg/day to placebo. The vertical axis represents mean change from baseline, with clinical improvement above baseline and clinical decline below. Donepezil shows an increase indicating improvement, while placebo trends toward decline.*

FDA Label Image

Figure 8 (Spl Image9 Figure8)

A cumulative percentage plot comparing patients treated with Donepezil Hydrochloride 10 mg/day and placebo, showing SIB change from baseline on the x-axis and cumulative percentage of patients on the y-axis. The graph visually contrasts the treatment and placebo groups over a range of SIB changes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.